Financial Management Professionals Inc. Purchases 361 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Financial Management Professionals Inc. lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,878 shares of the biopharmaceutical company’s stock after buying an additional 361 shares during the quarter. Financial Management Professionals Inc.’s holdings in Gilead Sciences were worth $431,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in GILD. Tompkins Financial Corp grew its stake in shares of Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares in the last quarter. Fortitude Family Office LLC bought a new stake in Gilead Sciences during the fourth quarter worth approximately $29,000. Private Wealth Management Group LLC bought a new stake in Gilead Sciences during the fourth quarter worth approximately $29,000. Sachetta LLC bought a new stake in Gilead Sciences during the fourth quarter worth approximately $30,000. Finally, Rakuten Securities Inc. bought a new stake in Gilead Sciences during the fourth quarter worth approximately $33,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $68.61 on Friday. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. The stock has a fifty day moving average price of $65.98 and a two-hundred day moving average price of $72.64. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86. The firm has a market capitalization of $85.48 billion, a P/E ratio of 190.58, a P/E/G ratio of 2.93 and a beta of 0.20.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The firm had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. During the same period in the prior year, the company posted $1.37 earnings per share. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, analysts anticipate that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 27th. Shareholders of record on Friday, June 14th were paid a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, June 14th. This represents a $3.08 annualized dividend and a yield of 4.49%. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Analyst Ratings Changes

A number of brokerages have issued reports on GILD. Barclays decreased their target price on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday, April 29th. Robert W. Baird reaffirmed a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a research report on Thursday, June 20th. Oppenheimer reaffirmed an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a research report on Friday, April 19th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $74.00 target price on shares of Gilead Sciences in a research report on Friday, June 14th. Finally, UBS Group cut their price target on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Twelve analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Hold” and an average price target of $83.47.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.